CLSD Clearside Biomedical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLSD

Price (delayed)

$1.01

Market cap

$61.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.55

Enterprise value

$48.98M

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS ...

Highlights
The revenue has plunged by 96% YoY and by 95% from the previous quarter
The company's gross profit has shrunk by 96% YoY and by 96% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://clearsidebio.com
Peers: OVID

Key stats

What are the main financial stats of CLSD
Market
Shares outstanding
61.36M
Market cap
$61.98M
Enterprise value
$48.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.73
Price to sales (P/S)
45.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.91
Earnings
Revenue
$1.33M
EBIT
-$32.95M
EBITDA
-$32.8M
Free cash flow
-$13.61M
Per share
EPS
-$0.55
Free cash flow per share
-$0.23
Book value per share
$0.18
Revenue per share
$0.02
TBVPS
$0.85
Balance sheet
Total assets
$51.3M
Total liabilities
$40.7M
Debt
$35.26M
Equity
$10.61M
Working capital
$43.62M
Liquidity
Debt to equity
3.32
Current ratio
8.54
Quick ratio
8.34
Net debt/EBITDA
0.4
Margins
EBITDA margin
-2,471.9%
Gross margin
84.6%
Net margin
-2,482.8%
Operating margin
-2,281.6%
Efficiency
Return on assets
-75.8%
Return on equity
-153.1%
Return on invested capital
-233.6%
Return on capital employed
-72.4%
Return on sales
-2,482.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLSD stock price

How has the Clearside Biomedical stock price performed over time
Intraday
-0.98%
1 week
3.06%
1 month
-24.06%
1 year
-57.2%
YTD
-9.82%
QTD
-9.82%

Financial performance

How have Clearside Biomedical's revenue and profit performed over time
Revenue
$1.33M
Gross profit
$1.12M
Operating income
-$30.28M
Net income
-$32.95M
Gross margin
84.6%
Net margin
-2,482.8%
The revenue has plunged by 96% YoY and by 95% from the previous quarter
The company's gross profit has shrunk by 96% YoY and by 96% QoQ
CLSD's gross margin is down by 15% from the previous quarter and by 15% YoY

Growth

What is Clearside Biomedical's growth rate over time

Valuation

What is Clearside Biomedical stock price valuation
P/E
N/A
P/B
5.73
P/S
45.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.91
CLSD's equity has dropped by 72% year-on-year and by 43% since the previous quarter
The price to book (P/B) is 29% higher than the last 4 quarters average of 4.5 but 18% lower than the 5-year quarterly average of 7.1
The revenue has plunged by 96% YoY and by 95% from the previous quarter
The P/S is 89% below the 5-year quarterly average of 426.9

Efficiency

How efficient is Clearside Biomedical business performance

Dividends

What is CLSD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLSD.

Financial health

How did Clearside Biomedical financials performed over time
The company's total assets is 26% higher than its total liabilities
The company's total assets rose by 20% YoY but it fell by 8% QoQ
The current ratio has contracted by 19% from the previous quarter and by 6% YoY
The debt to equity has soared by 91% from the previous quarter
CLSD's equity has dropped by 72% year-on-year and by 43% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.